Poland Cancer Centre begins clinical trial of HPV Serum Level and FDG PET CT in Patients With Cervical Cancer Treated With Radical Radiochemotherapy
The Greater Poland Cancer Centre is starting a new clinical trial of HPV Serum Level and FDG PET CT in Patients With Cervical Cancer Treated With Radical Radiochemotherapy.
The main purpose of the study is to describe changes in plasma HPV DNA levels in patients with locally advanced cervical cancer during radical radiochemotherapy (CRT) and to correlate changes with response to treatment. Monitoring of the response to treatment will also be assessed in FDG PET CT imaging.
Ninety-five per cent of cervical cancer cases are caused by persistent infections with carcinogenic HPVs. Locally advanced stage IB2 to IVA cervical cancers are treated with definitive chemoradiation therapy (CRT). Despite known clinical prognostic factors of poor treatment outcome such as advanced stage and positive nodal status, the researchers still don't know predictors of relapse.
Among the exclusion criteria are:
- Patients who have received any anticancer treatment for their cervical cancer.
- Eastern Cooperative Oncology Group (ECOG) performance status > 2
- Other cervical cancer tumor histologies (e.g. small cell, serous)
- Contraindications to 18FDG PET-CT
- Contraindication to radiochemotherapy
- Known pregnancy or lactating
The clinical trial started in June 15, 2020 and will continue throughout December 31, 2022.
The contacts and locations are the Greater Poland Cancer Centre, Poznan, Poland.
For more details: https://ichgcp.net/clinical-trials-registry/NCT04683549
